5-(tert-butyl)-3-isopropylisoxazole | 1291087-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(tert-butyl)-3-isopropylisoxazole
• 英文别名: 5-Tert-butyl-3-propan-2-yl-1,2-oxazole
• CAS: 1291087-58-5
• 化学式: C₁₀H₁₇NO
• 分子量: 167.251
• InChiKey: FEWZURCKMOEMGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (E)-2-methyl-N-(2,6,6-trimethylhept-4-yn-3-ylidene)propan-2-amine N-oxide 在 gold(III) chloride 、 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 26.0h， 生成 5-(tert-butyl)-3-isopropylisoxazole
  参考文献：
  名称：

  Zinc Triflate Catalyzed Aerobic Cross-Dehydrogenative Coupling (CDC) of Alkynes with Nitrones: A New Entry to Isoxazoles

  摘要：

  A mild, operationally simple cross-dehydrogenative coupling between nitrones and terminal alkynes is described by using cheap, readily available 3,3',5,5'-tetra-tert-butyldipheno-quinone and dioxygen as oxidants. These cross-couplings can be performed on various nitrones and alkynes with good to excellent yields. Product nitrones are readily transformed to pharmaceutically important 3,5-disubstituted isoxazoles.

  DOI：

  10.1021/ol200849k

文献信息

• MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS
  申请人：Macdonald Gregor James

  公开号：US20120238561A1

  公开（公告）日：2012-09-20

  The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic receptor agonists.

  本发明涉及吗啉噻唑衍生物及其可药用盐，它们的制备方法，含有它们的药物组合物及其在治疗中的用途。特别是涉及烟酸乙酰胆碱受体的正变构调节剂，这些正变构调节剂具有增加烟酸受体激动剂效力的能力。
• Imidazolothiazole compounds for the treatment of disease
  申请人：Bhagwat Shripad

  公开号：US20070232604A1

  公开（公告）日：2007-10-04

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了用于调节受体激酶活性以及用于治疗、预防或改善由受体激酶介导的一种或多种疾病或紊乱症状的化合物、组合物和方法。
• [EN] BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] BIARYLÉTHERSULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2013064984A1

  公开（公告）日：2013-05-10

  This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  这项发明涉及联苯醚磺酰胺，或其药用可接受的盐、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或症状，如疼痛。
• NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Moon Ho-Sang

  公开号：US20100063041A1

  公开（公告）日：2010-03-11

  The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

  本发明提供了一种新型苯丙酸衍生物，以及包含该衍生物作为活性成分的PPAR-γ调节剂。本发明的苯丙酸衍生物对PPAR-γ的功能具有调节作用，从而在PPAR介导的疾病或紊乱中表现出降糖、降脂和减少胰岛素抵抗的效果。因此，本发明在预防或治疗糖尿病和代谢性疾病方面具有预防或治疗效果。
• MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
  申请人：Dahl Russell

  公开号：US20070232648A1

  公开（公告）日：2007-10-04

  Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the structure where A, B, and R 1 -R 3 are defined herein.

  提供了一种新型的非类固醇化合物，它们是糖皮质激素受体调节剂，可用于治疗需要糖皮质激素受体激动剂或拮抗剂治疗的疾病，如肥胖症、糖尿病、炎症和免疫性疾病，并具有以下结构，其中A、B和R1-R3在此处定义。